1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional) is sponsored by National Institute on Drug Abuse (NIDA) / NIH HEAL Initiative. Part of the NIH HEAL Initiative, this funding opportunity supports the development of interventions to prevent and treat substance use disorders and overdose. It focuses on therapeutics development and may involve clinical trials.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional) | Research Funding National Institutes of Health Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional) The purpose of this notice of funding opportunity (NOFO) is to seek grant applications to support research on the discovery and development of interventions to prevent and/or treat substance use disorders (SUDs) and overdose, including interventions to treat co-morbid SUDs.
This includes preclinical and clinical research studies that will have high impact and quickly yield the necessary results to advance candidate interventions closer to regulatory approval or clinical adoption. This NOFO will utilize the UG3/UH3 activity code.
Application Due Date(s): Oct 20, 2025; Feb 20, 2026; June 22, 2026; Oct 20, 2026; Feb 22, 2027; June 21, 2027; Oct 20, 2027; Feb 22, 2028; June 20, 2028 AIDS Application Due Date(s): Dec 22, 2025; April 20, 2026; Aug 20, 2026; Dec 21, 2026; April 20, 2027; Aug 20, 2027; Dec 20, 2027; Apr 20, 2028; Aug 21, 2028 PAR-25-446 Expiration Date August 22, 2028 Application budgets are limited to $3 million per year for direct costs.
The maximum period of support is 5 years. The maximum period of support for the UG3 Phase is 2 years, and the maximum period of support for the UH3 Phase is 3 years. Medical - Clinical Science
According to the current listing, eligibility includes: Refer to the specific RFA/PA for detailed eligibility. Generally, academic institutions, research organizations, and other entities capable of conducting therapeutic development research. Confirm the full requirements in the official notice before applying.
Applications for Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional) are due August 21, 2028. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional) is funded by National Institute on Drug Abuse (NIDA) / NIH HEAL Initiative. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
HEAL Initiative: Translating Addiction Epidemiology, Prevention, Treatment, and Recovery Research into Practice (R61/R33 - Clinical Trial Optional) is sponsored by National Institute on Drug Abuse (NIDA) / NIH HEAL Initiative. This funding opportunity supports action-oriented research to accelerate the translation of addiction epidemiology, prevention, treatment services, and recovery research into practice to address the opioid crisis and/or overdose events.
HEAL Initiative: Research Studies to Develop and Implement Interventions to Prevent Opioid Misuse in Community Health Centers (RFA-DA-23-048) is sponsored by National Institute on Drug Abuse (NIDA) / NIH HEAL Initiative. This funding opportunity supports interdisciplinary teams to study the development, adaptation, and/or implementation of interventions to prevent misuse of opioids and other substances in community health centers.
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articlePA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read article